Investor Presentaiton

India Formulations business Branded business continued to display strong growth India Formulations Sales Q4 FY22 Revenue (Rs. mn) 10,232 10,785 11,640 Contribution 31% India Formulations Sales (Rs. mn) 48,125 40,429 Q4FY21 Q3FY22 Q4FY22 FY21 FY22 YOY 13.8% Q4 FY22 Gr. FY22 Gr. 19.0% QoQ 7.9% Large brands - a key growth driver TA-wise Break-up* # of Brands Others Anti- infectives 15% 27% 1000+ 8 Cardiac 15% " ◉ Highlights for the quarter zydus Dedicated To Life Ex. COVID opportunities, Gx portfolio and divested products, the branded prescription business grew by 19% YoY. Growth was well represented by volume expansion as well as better realization. Gained market share in key therapies viz. anti-diabetic, cardiovascular and gynecology on a YoY basis#. On the Super Specialty front, Retained leadership position in Nephrology segment* and ➤ Fastest growing Company in India in Oncology segment. With first in market launches like Ujvira™ and Exmeptia TM, biologics business has one of the largest portfolios and is among the fastest growing companies in respective therapeutic areas. Brand Value 500 to 1000 22 Respi 11% (Rs. Mn)* GI Pain 250 to 500 36 10% Gynae 6% 11% Derma 5% *Source: AWACS MAT March 22 #Source: AWACS Jan - Mar 2022 qtr. 6

View entire presentation